ERBB2 and breast neoplasm: In addition, ADCs are target-specific and, according to a study investigating the efficacy of an ADC comprised of trastuzumab and auristatin payloads against breast tumours, there was no evident toxicity observed against the HER2 negative cell line, HEK293, used in the study [50].